Connect your AI

TG Therapeutics TGTX Free cash flow

Free cash flow at other companies

BiogenBIIB

$594.3M+167%

BridgeBio PharmaBBIO

——

Krystal Biotech, Inc.KRYS

——

Arrowhead ResearchARWR

——

Roivant SciencesROIV

——

Neurocrine BiosciencesNBIX

——

Other financials

Income statement

Revenue$204.9M+69.6%

Gross profit$171.4M+62.8%

Operating income$34.8M+304%

Net income$19.8M+291%

EPS (diluted)$0.12+300%

Balance sheet

Cash & equivalents$442.2M+235%

Total debt$753.6M+197%

Total equity$583.1M+146%

Total assets$1.5B+133%

Cash flow

Operating cash flow-$17.9M+37.7%

CapEx$51.0K+104%

Valuation

Market cap$8.15B-14.3%

Enterprise value$8.46B-11.1%

P/E17.6×-225×

P/S11.6×-13.0×

Profitability

Gross margin83.1%-4.4pp

Operating margin21.3%+5.9pp

Net margin66%+55.8pp

FCF margin-6,328.4%+4,773pp

Returns & leverage

Return on equity112.6%+92.9pp

Debt / equity1.3×+0.2×

Current ratio5.8×+1.8×

Where this comes from

Calculated from TG Therapeutics’s reported figures.

−$17.9Mnet cash from operating−$51.0Kcapital expenditures=-$17.95M

The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about TG Therapeutics's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is TG Therapeutics's free cash flow?: TG Therapeutics (TGTX) reported free cash flow of -$17.95M in Q1 2026.
How has TG Therapeutics's free cash flow changed year-over-year?: TG Therapeutics's free cash flow increased by 37.6% year-over-year, from -$28.74M to -$17.95M.